Shinichiro Okauchi1, Yuika Sasatani1, Toshihiro Shiozawa2, Hideyasu Yamada3, Kunihiko Miyazaki4, Norio Takayashiki5, Hiroaki Satoh6. 1. Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan. 2. Division of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. 3. Division of Respiratory Medicine, Hitachinaka Medical Center, University of Tsukuba-Hitachinaka General Hospital, Hitachinaka, Japan. 4. Division of Respiratory Medicine, Ryugasaki Saiseikai General Hospital, Ryugasaki, Japan. 5. Division of Pathology, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan. 6. Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan hirosato@md.tsukuba.ac.jp.
Abstract
BACKGROUND/AIM: Pleomorphic carcinoma of the lung is a rare, highly malignant subtype of lung cancer, with a more aggressive clinical course compared with other types of non-small-cell lung cancer (NSCLC). Platinum-containing chemotherapy has been the standard therapy for patients with NSCLC and pembrolizumab is one of the novel and reliable agents for these patients. CASE REPORT: We herein report the case of a 60-year-old man with advanced chemo-naïve pleomorphic carcinoma of the lung who was successfully treated with a combination of pembrolizumab with platinum-containing chemotherapy. CONCLUSION: In the absence of definitive clinical trials, which are unlikely to be performed due to the rarity of this tumor, our case demonstrates the potential utility of the combination of pembrolizumab with platinum-containing chemotherapy. Our result also suggest that this combination of therapy may be key to the treatment of pleomorphic carcinoma of the lung. Copyright
BACKGROUND/AIM: Pleomorphic carcinoma of the lung is a rare, highly malignant subtype of lung cancer, with a more aggressive clinical course compared with other types of non-small-cell lung cancer (NSCLC). Platinum-containing chemotherapy has been the standard therapy for patients with NSCLC and pembrolizumab is one of the novel and reliable agents for these patients. CASE REPORT: We herein report the case of a 60-year-old man with advanced chemo-naïve pleomorphic carcinoma of the lung who was successfully treated with a combination of pembrolizumab with platinum-containing chemotherapy. CONCLUSION: In the absence of definitive clinical trials, which are unlikely to be performed due to the rarity of this tumor, our case demonstrates the potential utility of the combination of pembrolizumab with platinum-containing chemotherapy. Our result also suggest that this combination of therapy may be key to the treatment of pleomorphic carcinoma of the lung. Copyright